Abstract
Regadenoson (REG) appears to be safe in patients with end-stage renal disease (ESRD) on the basis of two retrospective studies. A prospective, placebo-controlled clinical trial by Palani et al found REG to be safe in chronic kidney disease (CKD) stage III-IV. However, there has not been a
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
